Radioimmunotherapy for Liver Cancer
Author Information
Author(s): A.F.M. Saiful Alam
Primary Institution: Hokkaido University School of Medicine
Hypothesis
The study evaluates the effects of '3'I-labelled antiferritin antibody on hepatocellular carcinoma in mice.
Conclusion
The treatment with '3'I-labelled antiferritin antibody led to significant tumor regression and prolonged survival in mice.
Supporting Evidence
- 55% of animals in the early treatment group showed tumor regression.
- 44% of animals in the late treatment group showed tumor regression.
- Median survival increased by 25% in the late treatment group compared to controls.
Takeaway
Researchers used a special antibody to treat liver cancer in mice, and it helped shrink the tumors and made the mice live longer.
Methodology
The study involved injecting athymic nude mice with a ferritin-producing human hepatocellular carcinoma cell line and treating them with radiolabelled antiferritin antibody.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Female athymic nude mice aged 6-8 weeks.
Statistical Information
P-Value
p=0.009
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website